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Abstract
Emerging evidence has demonstrated that miRNA sequences can regulate skeletal myogenesis by controlling the process of
myoblast proliferation and differentiation. However, at present a deep analysis of miRNA expression in control and FSHD
myoblasts during differentiation has not yet been derived. To close this gap, we used a next-generation sequencing (NGS)
approach applied to in vitro myogenesis. Furthermore, to minimize sample genetic heterogeneity and muscle-type specific
patterns of gene expression, miRNA profiling from NGS data was filtered with FC$4 (log2FC$2) and p-value,0.05, and its
validation was derived by qRT-PCR on myoblasts from seven muscle districts. In particular, control myogenesis showed the
modulation of 38 miRNAs, the majority of which (34 out 38) were up-regulated, including myomiRs (miR-1, -133a, -133b and
-206). Approximately one third of the modulated miRNAs were not previously reported to be involved in muscle
differentiation, and interestingly some of these (i.e. miR-874, -1290, -95 and -146a) were previously shown to regulate cell
proliferation and differentiation. FSHD myogenesis evidenced a reduced number of modulated miRNAs than healthy muscle
cells. The two processes shared nine miRNAs, including myomiRs, although with FC values lower in FSHD than in control
cells. In addition, FSHD cells showed the modulation of six miRNAs (miR-1268, -1268b, -1908, 4258, -4508- and -4516) not
evidenced in control cells and that therefore could be considered FSHD-specific, likewise three novel miRNAs that seem to
be specifically expressed in FSHD myotubes. These data further clarify the impact of miRNA regulation during control
myogenesis and strongly suggest that a complex dysregulation of miRNA expression characterizes FSHD, impairing two
important features of myogenesis: cell cycle and muscle development. The derived miRNA profiling could represent a novel
molecular signature for FSHD that includes diagnostic biomarkers and possibly therapeutic targets.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is the third
most common myopathy, with an incidence of 1 in 14.000 in the
general population. Signs of FSHD become visible in an
individual’s 20’s (men) or 30’s (women) and include loss of muscle
strength in the face, shoulders, and upper arms before eventually
attaining the abdomen, legs and feet. FSHD is transmitted as an
autosomal dominant trait and it is thought to be mainly associated
to an epigenetic alteration leading to transcriptional imbalance of
the responsible genes [1,2]. Almost all FSHD patients carry
rearrangements reducing the copy number of a 3.3 kb tandemly
repeated sequence (D4Z4) located at 4q35, and containing a
conserved open reading frame for a double homeobox gene
(DUX4). D4Z4 copy number is highly polymorphic in healthy
individuals ranging between 11 and .100copies while FSHD
patients carry fewer than 11 repeats [3]. Notably, although the
number of D4Z4 repeats seems to be a critical determinant of the
age of onset and clinical severity of FSHD, patients without D4Z4
contraction (phenotypic FSHD or FSHD2) as well as healthy
individuals with D4Z4 contraction (carrier) have been also
identified [4,5]. All these observations strongly suggests that
FSHD derives from the interplay of more complex genetic and
epigenetic events than those already described; these additional
events might take place at either 4q35 or elsewhere in the human
genome.
Recently a unifying genetic model [6] that provides the
expression of D4Z4 as a major cause of FSHD has been proposed.
Another recent paper [7] defining the epigenetic regulation of
4q35 gene expression, demonstrated that D4Z4 deletion is
associated to reduced epigenetic repression by Polycomb silencing
in FSHD patients. Furthermore, DBE-T, a chromatin associated
non-coding RNA is produced selectively in FSHD patients and it
coordinates the de-repression of 4q35 genes. However, another
study evaluating a large-scale population analysis of healthy and
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Figure 1. Study design and data analysis. A) Study design: Next-generation Sequencing (NGS) on three control and three FSHD myoblast cell
lines before and after in vitro myogenic differentiation was used in order to derive miRNA modulation in: a) control myogenesis (CN myotubes vs CN
myoblasts; arrow a); b) FSHD myogenesis (FSHD myotubes vs FSHD myoblasts; arrow b); c) FSHD myoblasts versus control myoblast (arrow c), and d)
FSHD myotubes vs control myotubes (arrow d). B) Flow chart of filtering and analysis of NGS data. NGS generated a total of 1536106 high quality
reads, that were filtered for rRNA, tRNA, snRNA, snoRNA, repeat associated RNAs and intron/exon. The filtered reads (approx. 996106 reads, an
average of 86106/sample) were analyzed to derive known miRNAs (R/Bioconductor) and novel miRNAs (mireap). Differentially expressed miRNAs
between samples were derived by log2FC§2 and p-value,0.05 parameters. The homogeneity of miRNA modulation among samples was evaluated
by cluster analysis (dChip). miRNAs were then validated by qRT-PCR. Finally, target genes were predicted for modulated miRNAs and functionally
annotated by DAVID.
doi:10.1371/journal.pone.0108411.g001
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unrelated FSHD patients reports that the genetic criteria in order
to manifest FSHD (D4Z4 contraction associated with a specific
chromosomal background 4A-161-p(A)- pathogenic haplotype)
occur in 63.7% of the analyzed FSHD patients and in 1.3% of
healthy subjects [8]. Although these data certainly represent a
major advance toward the definition of the molecular basis of
FSHD, many questions on the disease etiology remain unex-
plained. Also the reported high degree of variability of the disease,
in term of onset, progression and severity strongly suggests that
other mechanism(s) linked to the 4q subtelomere and/or to other
regions of the human genome may play a role in the disease
pathogenesis.
Various recent studies have demonstrated that both FSHD
myoblasts and myotubes are characterized by an extensive gene
expression dysregulation mainly affecting the myogenesis and
including genes linked to cell cycle control, particularly G1/S and
G2/M transitions, muscle structure, mitochondrial function,
oxidative stress response, and cholesterol biosynthesis [9,10,11].
The deciphering of the molecular basis of FSHD has been
further complicated by the finding that microRNAs (miRNAs) are
involved in both control and pathological myogenesis [12,13,14].
MiRNAs are evolutionarily conserved short non-coding RNAs
(,22 nts) that regulate the stability and/or the translational
efficiency of target mRNAs. They have a very pervasive role since
it is estimated that a single miRNA has the potential to regulate
hundreds of target genes, and therefore,.90% of all human genes
could be under miRNAs regulation [15]. MiRNAs are essential for
normal mammalian development and are involved in fine-tuning
of many biological processes, such as differentiation, proliferation
and apoptosis [16,17]. Emerging evidence has demonstrated that
miRNA sequences can regulate skeletal myogenesis by controlling
the process of myoblast proliferation and differentiation, in
particular, microRNA-1, -206 and -133a/b were defined as
myomiRNAs to emphasize their crucial role in myogenesis
[18,19]. More recently, a simultaneous microRNA/mRNA
expression profiling of healthy myogenic cells during differentia-
tion allowed to identify the involvement of miRNAs in the
regulation of various biological processes such as cell cycle,
transcription, transport, apoptosis and DNA damage [20]. Given
these assumptions it was not surprising that miRNAs dysregulation
was found to be involved in muscle dysfunctions [9,12,21].
To date, miRNA studies reported for FSHD were essentially
based on the analysis of a restricted number of known miRNA
sequences, thus not allowing the derivation of the full miRNA-
based dysregulation network. To close this gap, here we report
miRNAs expression analysis, derived by next-generation sequenc-
ing (NGS), in primary muscle cells from healthy and FSHD
subjects during differentiation.
Results
Study design and NGS general results
In order to determine the entire small non coding RNAs (,
35 nts) transcriptome in control (CN) and FSHD primary
myoblast cell lines, before and after in vitro myogenic differen-
tiation, we used next-generation sequencing (NGS). Study design
was organized to allow the comparison of small non-coding RNA
expression profiles between FSHD and CN myoblasts and
myotubes (Fig. 1A, arrows c and d respectively) and of the two
differentiation processes (Fig. 1A, arrows a and b, respectively). In
order to derive biological markers (i.e. miRNA dysregulation)
commonly manifested by different affected muscle districts, we
used two FSHD primary myoblasts cell lines deriving from
rhomboid and one from ilio-psoas muscles, and three control
myoblasts from tensor fascia lata, quadriceps and vastus interme-
dius (Table S1).
As shown in the flow chart reported in Fig. 1B, small RNA
sequencing generated a total of 1536106 high quality reads.
Mature miRNAs make up the majority of sequences in the 18 to
25 nts size range (65% average), with a clear peak at 22 nts in all
samples. The average of known miRNAs per sample was of 556,
whereas un-annotated small RNAs (new miRNA candidates) per
sample were 28.
The differential expression of known miRNAs was analyzed in
the different stages of muscle differentiation by DEseq analysis.
Furthermore, in order to assess the robustness of our approach,
some of the miRNAs identified as differentially expressed were
validated by qRT-PCR using specific TaqMan miRNA assays in
primary FSHD and healthy myoblasts. For these experiments we
employed the same cell lines used for NGS and additional ones
from different muscles, including biceps and deltoid (Table S1). As
reported in Materials and Methods, the nine control and the seven
FSHD cell lines showed a highly comparable extent of Desmin-
positive cells and of myogenic markers modulation upon
differentiation (Fig. S1). Gene targets of differentially expressed
miRNAs were predicted in both control and FSHD cellular
systems by using the TargetScan algorithm. Derived gene targets
were filtered on two independent transcriptome profiling exper-
iments carried out on control and FSHD myogenesis [9,10], and
shared targets were then functionally annotated by DAVID. Novel
miRNAs were predicted by mireap and considered as novel
candidates only if detected with a mean reads of ten in at least two
out of three samples of one or more experimental groups (CN and
FSHD myoblasts; CN and FSHD myotubes).
Modulation of miRNA expression during physiological
and FSHD myoblast differentiation
We first analyzed the data regarding physiological myogenesis
(control myotubes vs control myoblasts; Fig. 1A, arrow a). Filtered
miRNA reads (mapping to miRBase v20) from the three control
myoblasts samples and the corresponding myotubes were analyzed
for differential expression by DEseq analysis, setting the log2 Fold
Change (log2FC) at $2 and p-value,0.05. From this analysis we
evidenced that during the control myogenesis 38 miRNAs showed
a modulation in their expression, and that the great majority of
them (34 out of 38) were up-regulated (Fig. 2A and B).
The hierarchical clustering analysis clearly separated prolifer-
ating from differentiated cells independently of the muscle district
used (tensor fascia lata, quadriceps and vastus intermedius). As
expected, the muscle specific miRNAs (myomiRs) hsa-miR-1,
-133a, -133b and -206, were among the most up-regulated
(Fig. 2B and Table S3). Twenty-six miRNAs were already
reported to be involved in muscle differentiation either in human
or in mouse cells, whereas 12 miRNAs, ten up-regulated (hsa-miR-
95, -146a, -874, -1246, -1290, -3164, -4488, -208a, -944 and
-3144) and two down-regulated (hsa-miR-3934 and -3165), were
not previously known to be involved in muscle differentiation. The
full list of the miRNAs modulated during control myoblasts
differentiation with corresponding FC and p-value is reported in
Table S3.
The same analysis was carried out on FSHD myogenesis
(Fig. 1A, arrow b). As shown in Fig. 3A, the DEseq analysis
evidenced the modulation of only 15 miRNAs during pathological
muscle differentiation. Even in this case the hierarchical clustering
analysis clearly separated proliferating from differentiated cells,
independently of the muscle district (Fig. 3B). The majority of
miRNAs was up-regulated (11 out of 15), including myomiR-1 and
-206, although with a FC lower than that showed in control
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myogenesis (Table S4). MyomiR-133a and -133b showed up-
regulation trend (log2FC.5) without reaching significance (p-
value = 0.33). The full list of the miRNAs modulated in FSHD
myogenesis, with corresponding FC and p-value, is reported in
Table S4. Scatter plots of the reads of modulated miRNAs (for
each control and FSHD proliferating and differentiated cell line)
are reported in Fig. S2. To further support the results obtained by
the sequencing approach, the same control and FSHD myoblast
and myotube RNAs were used to analyze the expression of
myomiRs (miR-1, miR-133a and miR-206) by qRT-PCR (Fig.
S3). In both control and FSHD myotubes, we confirmed the
general trend of myomiRs up-regulation derived by sequencing,
with the pathological samples showing a lower extent of up-
regulation than the normal ones.
Dysregulation of miRNA expression in FSHD myoblasts
and myotubes
We next performed DEseq analysis of miRNAs differentially
expressed in FSHD myoblasts and myotubes vs controls (Fig. 1,
arrows c and d). No miRNAs were found significantly dysregulated
(log2FC$2 and p-value,0.05) in FSHD versus control myoblasts
(Fig. 1, arrows c); this result was probably due to the high
variability of miRNA expression observed in myoblasts. Con-
versely, 21 miRNAs were found dysregulated in FSHD myotubes
(Table S5 and Fig. 4A), among these 12 miRNAs were up-
regulated. The hierarchical clustering analysis clearly separated
the pathological samples from the control ones and the three
analyzed samples of each group resulted homogeneous in miRNAs
dysregulation (Fig. 4B).
Figure 2. MiRNA modulation in control myogenesis. A) DEseq analysis of miRNAs differentially expressed in control myotubes vs control
myoblasts (control differentiation). MiRNAs showing a modulation with log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical
clustering of the 38 modulated miRNAs (34 up-regulated and 4 down-regulated) in regard to the analyzed samples. C1:MX01010MBS; C2:
MX03609MBS; C3: MX01110MBS, Control cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g002
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qRT-PCR Validation
The effective validation of deep sequencing results was
performed by the TaqMan miRNA assay on all the cell lines
listed in Table S1, including those already used for the NGS
experiment. Particularly, for myomiR-1, -133a and -206 the assay
was carried out at different time points during myogenic
differentiation (0, 3 and 7 days of differentiation) (Fig. 5A). In
control cells, the myomiRs progressively increased their expression
with the proceeding of time of differentiation, reaching the
maximum of expression at seven days, with FC values ranging
from approximately 350 folds (miR-1) to 28 folds (miR-206). In
FSHD cells myomiRs showed an up-regulation significantly lower
than that observed in controls, reaching at day seven an expression
value similar to or slightly lower than that showed by control cells
at day three. Comparable fusion indexes and expression values of
myogenic markers in healthy and FSHD myoblasts and myotubes
(see Fig. S1) support that the obtained results are not related to a
Figure 3. MiRNA modulation in FSHD myogenesis. A) DEseq analysis of miRNAs differentially expressed in FSHD myotubes vs FSHD myoblasts
(FSHD differentiation). MiRNAs showing a modulation with log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical clustering of the 15
modulated miRNAs (11 up-regulated and 4 down-regulated) in regard to the analyzed samples. F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS,
FSHD cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g003
Figure 4. MiRNA dysregulation in FSHD myotubes. A) DEseq analysis of miRNAs differentially expressed in FSHD myotubes vs control
myotubes. MiRNAs showing a differential expression of log2FC$2 and a p-value,0.05 are shown as red dots. B) Hierarchical clustering of the 21
modulated miRNAs (12 up-regulated and 9 down-regulated) in regard to the analyzed samples. C1:MX01010MBS; C2: MX03609MBS; C3:
MX01110MBS, Control cell lines; F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS, FSHD cell lines (see Table S1).
doi:10.1371/journal.pone.0108411.g004
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different extent of differentiation between control and pathological
samples.
Six additional miRNAs were evaluated for their expression by
qRT-PCR (Fig. 5B). As shown in Fig. 5 and summarized in
Table 1, the qRT-PCR assays validated about the 70% of the
analyzed NGS data. Particularly, the up-regulation of hsa-miR-
139 and hsa-miR-146b during, respectively, FSHD and control
myogenesis, and the down-regulation of hsa-miR-206 in FSHD vs
CN myotubes did not reach the statistical significance showed by
NGS results, while maintaining the same trend. On the contrary,
the up-regulation of miR-133a in FSHD myogenesis, the down-
regulation of hsa-miR-1 and hsa-miR-133a in FSHD vs CN
myotubes, and the down-regulation of hsa-miR-155 in FSHD
myogenesis already observed in the NGS analysis became
significant in the qRT-PCR analysis.
Comparison of FSHD and control myogenesis
The comparison of miRNA modulation between control and
FSHD differentiation processes is reported in Fig. 6A, where black
and striped bars identify the Fold Change of miRNAs up- and
down-regulated, respectively, in control and FSHD myogenesis.
From this comparison it was possible to derive that FSHD
differentiation lacks the modulation of 29 miRNAs, the majority of
which (27/29) was up-regulated in control differentiation (black
bars in Fig. 6A, and Fig. 6B); while six miRNAs (4 up- and 2
down-regulated) were modulated only during the FSHD differen-
tiation process (striped bars in Fig. 6A and Fig. 6B). Nine miRNAs
showed the same trend in both processes (Fig. 6A and B), but with
differences in Fold Change values. Among these, miRNAs pivotal
for the myogenic process, such as hsa-miR-1, -206 and -222, were
included. Thus, FSHD myogenesis differs from control myogenesis
for the complete (35) or partial (9) dysregulation of a total of 44
miRNAs.
Figure 5. Validation of NGS data. A) qRT-PCR analysis of myomiRs (miR-1, miR-133a and miR-206) during control and FSHD myogenesis at 0, 3
and 7 days of differentiation. B) qRT-PCR analysis of six microRNAs modulated in control and/or FSHD myogenesis. GM: growth medium; 3D: 3 days of
differentiation; 7D: 7 days of differentiation. * p-value,0.05; ** p-value,0.01; *** p-value,0.001.
doi:10.1371/journal.pone.0108411.g005
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Prediction of miRNA target genes
To understand the functional impact of miRNA dysregulation
during FSHD myogenesis we used TargetScan prediction software
to derive potentially affected targets. In order to improve target
prediction accuracy, a common approach is to combine the output
of two or more prediction algorithms, however this strategy has
been proved inefficient [20]. Therefore, we have used a single
algorithm, TargetScan, which uses many parameters to predict
target scoring without omitting miRNAs with multiple target sites
[22]. Since the binding of a miRNA to the 39 UTR of its mRNA
target predominantly act to decrease target mRNA levels [23] we
decide to essentially focalize our attention on mRNA targets
showing an opposite expression value compared to the analyzed
miRNA. Normally, this approach has been carried out on mRNA
expression profile derived by using the same cells from which the
miRNA expression profile has been derived [11,20,21]. However,
the comparison of mRNA expression profiles derived by myoblast
cell lines or biopsies from different FSHD patients and controls
clearly evidenced a certain variability in the obtained results
[5,9,10,11,24,25]. In addition, mRNA expression differences were
also found by analyzing different muscles, such as biceps and
deltoids [11]. To reduce sample variability, we filtered the
predicted mRNA targets on two chip expression data
(GSE26061 [9]; GSE26145 [10]), sharing in vitro myogenic
differentiation protocol and platform although using primary
FSHD and control cell lines different from those analyzed in this
work. Functional classes corresponding to the filtered mRNAs
were assigned by DAVID Gene Ontology Database (Table 2). As
shown in Fig. 6, control myogenesis showed the modulation of 38
miRNAs (4 down- and 34 up-regulated), whereas FSHD
myogenesis was characterized by 15 dysregulated miRNAs (4
down- and 11 up-regulated) and the lack of modulation of 29
miRNAs. Applying the rationale described above, we derived a
total of 139 and 78 down- and up-modulated mRNAs in control
myogenesis (potentially ‘‘validated’’ target, Table S6), and a total
of 37 down- and 18 up-regulated transcripts in FSHD myogenesis
(potentially ‘‘validated’’ target, Table S7). In control myogenic
differentiation, the majority of down-regulated genes belonged to
cell cycle (27 entries), DNA metabolic process (17 entries),
cytoskeleton organization (11 entries), angiogenesis (8 entries)
and signal transduction (19 entries); genes involved in cell adhesion
(9 entries), regulation of cell migration (5 entries), muscle
development (7 entries), lipid biosynthetic process (6 entries) and
response to insulin (4 entries) were found up-regulated (Table 2).
Conversely, in FSHD myogenesis genes belonging to muscle
development (3 entries) and cell adhesion (5 entries) were down-
regulated, whereas those involved in regulation of signal trans-
duction (3 entries) were up-regulated. All the identified biological
processes, except the down-regulation of cell adhesion in FSHD
samples, showed a significant p-value ranging from 3.4E-10 to
3.2E-02 (see Table 2). It is noteworthy that target genes involved
in two important biological processes of myogenesis (i.e. cell cycle
and striated muscle development) subjected to miRNA control
were, as expected, down- and up-regulated, respectively, in control
cells. In FSHD myogenesis, on the contrary, the cell cycle was not
down-regulated, and control of striated muscle development was
down-regulated. It is important to notice that this analysis did not
take into account the different FC showed by the nine miRNAs
shared by control and FSHD myogenesis.
Identification of novel miRNAs
To identify novel potential miRNAs involved in human muscle
system, the unclassified tags were further processed by mireap
(http://sourceforge.net/projects/mireap). We considered only
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tags meeting the default parameters, expressed in all experimental
groups or preferentially expressed in one or more sample groups
(i.e. proliferating vs differentiated cells, or FSHD vs control cells)
and with mean read counts per group greater than ten. By using
these criteria we identified a total of 13 novel candidate miRNA
genes. In Table S8 are reported the main features of these novel
miRNA genes, including chromosome location and genomic
organization, mfe (minimum free energy), sequence and structure
of hairpin precursor, and sequence of 5p or 3p. A summary of
these data is reported in Table 3: six miRNAs showed a
preferential expression in myoblasts (both in FSHD and control)
and four miRNAs seemed to be specific for myotubes. The
remaining three miRNAs characterized all the considered groups
(both control and FSHD myoblasts and myotubes). Among the 13
Figure 6. Comparison of miRNA modulation in control and FSHD myogenesis. A) Black and striped bars identify the Fold Change of
miRNAs modulated respectively, in control and FSHD myogenesis. Bars on the left and on the right represent, respectively, down- and up-regulated
miRNAs. *hsa-mir-208a showed infinite FC value (see Table S3). B) Venn diagram showing the number of miRNAs unique to FSHD (white) or control
(grey), and shared (light grey) by FSHD and control differentiation processes.
doi:10.1371/journal.pone.0108411.g006
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novel miRNAs, two miRNAs (namely hsa-miR-m1-3p and hsa-
miR-m13-5p) had already been detected by analyzing prostate and
breast tumor cells [26,27] and the mature hsa-mir-m9-3p showed
100% sequence similarity with hsa-mir-574 whose gene however
differs in genomic location [28].
Furthermore, it is interesting to note that no sample showed
reads generated from the D4Z4 region. This observation, derived
either by the analysis of the filtered out repeats or by the re-
mapping NGS raw data to specific D4Z4-bearing chromosome
regions such as 4q and 10q, suggests that short transcribed
sequences from D4Z4 array may have a length greater than
35 nts, the threshold used to build our libraries.
Discussion
The paper reports the first complete analysis of miRNA
modulation during in vitro differentiation in both control and
FSHD-derived myogenic cells. Myogenesis is a complex process
that includes proliferation, differentiation, and formation of
myotubes and myofibers. These molecular events are regulated
by myogenic factors and miRNAs. MiRNAs specifically expressed
in skeletal and cardiac muscles are called myomiRs, to imply their
important roles in the regulation of muscle development and
differentiation [13,19,29]. Recently miRNA dysregulation has
been reported in FSHD [9,12,21]. However, due to the
approaches used, these studies were limited for the number and
type of miRNAs that could be simultaneously investigated; in
addition they would not detect miRNAs expressed at low level and
excluded discovery of novel miRNAs. Thus, to get the whole
pattern of miRNA dysregulation in FSHD we used a next-
generation sequencing (NGS) approach. Previous work aimed at
identifying biomarkers in FSHD by the transcriptional profiling
found muscle-type specific patterns of gene expression [11].
Similarly, DUX4-fl expression was found to vary between
myotubes derived from different muscle groups [30]. Therefore,
we tailored the experimental protocol to derive FSHD and control
miRNA profiles common to different muscles. To this aim, due to
inter-individual genetic heterogeneity, from deep sequencing data
we considered only miRNA modulation with FC$4 (log2FC$2)
and p-value,0.05. Then the derived miRNA expression in both
FSHD and control myogenesis was validated by qRT-PCR in all
the available FSHD and control cell lines.
Control myogenesis showed the modulation of 38 miRNAs, the
majority of which (34 out 38) were up-regulated. The up-regulated
miRNAs included those previously identified as key regulators of
both proliferation and differentiation of myogenic cells and for this
reason called myomiRs: hsa-miR-1, -133a, -133b and -206
[19,31,32]. The obtained results are in agreement but also expand
what is known about miRNA modulation during in vitro human
myogenic differentiation. Among the modulated miRNAs, 27
were in fact already reported to be involved in muscle
differentiation either in human or in mouse cells [20,33].
Conversely, 12 miRNAs, ten up-regulated (hsa-miR-95, -146a, -
874, -1246, -1290, -3164, -4488, -208a, -944 and -3144) and two
down-regulated (hsa-miR-3934 and -3165), were not previously
detected to be differentially expressed during control myogenesis.
In comparison with a previous work [20], the reduced number of
modulated miRNAs during control myogenesis that we derived is
probably due to the choice of higher FC value (FC$4).
Furthermore, the observed up-regulation of myomiRs strongly
supports the validity of used cell lines and differentiation protocol.
Interestingly, some up-regulated miRNAs not previously reported
to be involved in muscle differentiation, were previously shown to
affect cell proliferation by targeting HDAC1 (hsa-miR-874),
impairing cytokinesis (hsa-miR-1290), inhibiting cell growth (hsa-
miR-95) and regulating differentiation of smooth muscle cells (hsa-
miR-146a) [34,35,36,37].
Control myogenesis also showed the possible involvement of
some of the novel miRNAs we derived by NGS. In this regard, six
out of the 13 identified novel miRNAs (see Table 3) seem to
characterize the proliferating status of muscle cells (myoblasts,
miR-m2-3p, -m3-3p, -m4-5p, -m7-5p, -m12-3p, and –m13-5p)
and one the differentiated status (myotubes, miR-m6-3p). Two,
hsa-miR-m1-3p, and hsa-miR-m13-5p, have been previously
identified by the NGS approach and validated in breast and
prostate cancer cells (identified respectively as hsa-miR-B19 and
hsa-novel-miR-08) [26,27]. Further experiments are thus neces-
sary to validate and determine the possible involvement in muscle
cells differentiation of these novel miRNAs.
The comparison of control and FSHD myogenesis clearly
evidenced a reduced number of modulated miRNAs in FSHD
than in control muscle cells, thus suggesting that a complex
dysregulation of miRNA expression characterizes the dystrophy.
In total, nine miRNAs were shared between the two processes and
Table 2. Functional classification of predicted target genes in control and FSHD myogenesis.
Biological processes CONTROL MYOGENESIS FSHD MYOGENESIS
Down (p-value) Up (p-value) Down (p-value) Up (p-value)
Cell cycle +(3.4E-10)
DNA metabolic process +(2.8E-06)
Cytoskeleton organization +(2.7E-03)
Angiogenesis +(1.2E-03)
Signal transduction +(8.2E-03) +(3.2E-02)
Cell migration +(6.0E-03)
Cell adhesion +(1.2E-02) +(7.4E-02)
Striated muscle development +(1.6E-02) +(5.8E-03)
Sterol biosynthetic process +(1.0E-02) +(5.0E-04)
Response to insulin +(3.4E-03)
Functional classification of predicted target genes of modulated miRNAs in control and FSHD myogenesis, filtered on GSE26061 [9] and GSE26145 [10]. For full lists of
considered miRNAs and predicted target genes refer to Tables S3, S4 and S6, S7, respectively.
doi:10.1371/journal.pone.0108411.t002
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these included myomiR-1 and -206, with FC values of up-
regulation during differentiation lower than those derived for
control cells. Moreover, qRT-PCR analysis proved that in control
cells the up-regulation of myomiRs is higher than in FSHD ones
by a FC ranging from 2.4–5.56 for hsa-miR-206 and 133a to 136
for hsa-miR-1. Furthermore, the kinetic of myomiRs up-regulation
during FSHD myogenesis strongly suggests a defect in late stages
of the differentiation process. Other differences between control
and FSHD differentiation are represented by six miRNAs (i.e. hsa-
miR-1268, -1268b, -1908, 4258, -4508- and -4516) not modulated
in control cells and that therefore could be considered FSHD-
specific, likewise three novel miRNAs (hsa-miR-m5-5p, hsa-miR-
m10-5p and hsa-miR-m11-5p) that seem to be specifically
expressed in FSHD myotubes (see Table 3). Of interest, hsa-
miR-1268 exhibited a significant differential expression during the
differentiation of pluripotent human embryonic stem cells into
embryoid bodies [38]. In summary, FSHD myogenesis differed
from control myogenesis by the loss of modulation of 29 miRNAs
(black bars in Fig. 6A, and Fig. 6B) and the acquisition of
modulation of six miRNAs, two down-regulated and four up-
regulated (striped bars in Fig. 6A, and Fig. 6B). Among the nine
miRNAs shared by the two differentiation processes (black and
striped double bars in Fig. 6A), the myomiRs showed a significant
deficit of expression in late phases of FSHD differentiation.
Moreover, the comparison of miRNA expression between control
and FSHD myoblasts or myotubes detected 21 dysregulated
miRNAs only in myotubes (12 up-regulated and 9 down-
regulated). The lack of differentially expressed miRNAs in FSHD
myoblasts may be explained both by a high variance of miRNA
expression showed by myoblasts and by the high FC used.
Some discrepancies between the data we derived and those
recently reported in a similar cellular system [21] require several
considerations. First, the methodological approach (NGS against
transcriptome profiling), and consequently the cut-off used make
the results obtained not comparable; second, both healthy and
FSHD myoblast cell lines characterized by a high percentage of
DES+ cells were induced to differentiate for three days [20] and
for seven days (herein). Lastly, our study design was set up in order
to derive a FSHD miRNA profiling possibly shared by different
muscle districts and including all the microRNAs present in
miRBase (release 20), as well as novel miRNAs. In this regard, it is
noteworthy that if we had used the microRNA panel version 1.0 (a
TaqMan low density array containing 365 miRNAs) instead of the
NGS approach, we would have only detected the modulation of
five miRNAs during differentiation of FSHD myoblasts (namely
hsa-miR-1-1, 1-2, -206, -222 and -139), instead of the fifteen
effectively found (see Table S4). Thus, as previously shown in
other cellular systems [26,27,39,40] the deep sequencing approach
allowed us to derive a more complete view of miRNA
dysregulation in FSHD.
Our data strongly suggest that, in addition to the recently
reported up-regulation in proliferating FSHD vs control cells,
which however did not result in a complete down-regulation of the
corresponding target genes [21], a defect of myomiRs expression
also characterize late stages of FSHD differentiation. In fact, the
extent of myomiRs expression in FSHD cells after seven days of
differentiation was similar to or lower than that found at three days
in control cells. Thus, besides the reported up-regulation of
myomiRs in FSHD myoblasts due to the early euchromatization
of their promoters [21] other defects could be responsible of their
down-regulation during late stages of differentiation. In this regard
it is possible to hypothesize a defect in FSHD myotubes at the
myomiRs transcriptional or post-transcriptional levels, such as a
decrease of myogenic differentiation factors controlling their
transcription (i.e. MEF2) [41], or of factors controlling their
processing. The latter hypothesis agrees with previous results
showing that FSHD myotubes are characterized by the down-
Table 3. Novel miRNAs predicted by mireap.
Name Chromosome location Mature miRNA sequence Length
Genomic
context
Expression
n.samples Other evidence
hsa-miR-m1-3p chr11:122022800–122022877 AAAAGGGGGCTGAGGTGGAGG 21 intronic 12/12 (higher
expression in
myoblasts)
PMID:21346806
hsa-miR-m2-3p chr11:125757935–125758025 AGGGGCGCGGCCCAGGAGCTCAGA 24 intronic 5/6 myoblasts no
hsa-miR-m3-3p chr13:111102986–111103008 AGCTGGGGATGGAAGCTGAAGCC 23 intronic 4/6 myoblasts no
hsa-miR-m4-5p chr14:74998697–74998789 CTGCTCTGATGTCTGGCTGAGC 22 intronic 5/6 myoblasts No
hsa-miR-m5-5p chr15:41592311–41592403 ATCATTTGGCAGGGGGTAGAGTA 23 intergenic 3/3 FSHD
myotubes
No
hsa-miR-m6-3p chr15:45493361–45493452 TTGTGGAAACAATGGTACGGCA 22 overlaps repeat/tRNA 4/6 myotubes No
hsa-miR-m7-5p chr17:8042708–8042779 GAGTTAGCGGGGAGTGATATATT 23 overlaps repeat/tRNA 4/6 myoblasts No
hsa-miR-m8-3p chr:6:28918819–28918903 TCGGGCGGGAGTGGTGGCTTTT 22 overlaps repeat/tRNA 12/12 No
hsa-miR-m9-3p chr8:79679467–79679541 TGAGTGTGTGTGTGTGAGTGTGA 23 intronic 9/12 (all groups) mature miRNA identical
to hsa-mir-574, different
genomic location
PMID:17604727
hsa-miR-m10-5p chrX:18651329–18651427 AACTTTGGAATGTGGTAGGGTA 22 intronic 3/3 FSHD
myotubes
No
hsa-miR-m11-5p chrX:40478974–40479066 ATCATTTGGCAGGGGGTAGAGTA 23 intergenic 3/3 FSHD
myotubes
No
hsa-miR-m12-3p chr13:111102941–111103018 AGCTGGGGATGGAAGCTGAAGCC 23 intronic 4/6 myoblasts No
hsa-miR-m13-5p chr20:3194751–3194835 CAAAATGATGAGGTACCTGATA 22 Intronic 6/6 myoblasts PMID:21152091
doi:10.1371/journal.pone.0108411.t003
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regulation of a gene (Dicer1) controlling the cytoplasmic matura-
tion of pre-miRNAs [10].
Our data allowed us to confirm a few miRNAs previously found
dysregulated by independent analysis of ten major skeletal muscle
disorders, including FSHD [12,42]. Among the miRNAs we
derived to be deregulated during FSHD muscle differentiation,
four miRNAs (miR-146a, -146b, -155, -222) were consistently
found up-regulated in six or more muscular disorders, including
FSHD, whereas miR-501 was found dysregulated in five muscle
diseases, but not in FSHD. Furthermore miRNA-486, a muscle
enriched miRNA, previously found significantly reduced in
patients with DMD [12], was found up-regulated in the present
study. Interestingly overexpression of this miRNA in mouse
primary myoblasts resulted in increased proliferation and thus in
altered cell-cycle kinetics [43].
In order to understand the functional outcome of miRNA
dysregulation in FSHD, the derived up- and down-regulated
target genes were functionally clustered into biological processes.
This approach when applied to healthy muscle differentiation
evidenced two important features of myogenesis: cell cycle and
muscle development. Effectively, as muscle differentiation pro-
ceeds, sustained by the up-regulation of myogenic markers (due to
the down-regulation of the corresponding miRNA regulators), the
cell proliferation program must slow down due to the up-
regulation of miRNA controlling genes involved in this process.
An opposite trend of the two biological processes was found to
characterize FSHD myogenesis. In fact, down-regulated genes
were essentially involved in the regulation of striated muscle tissue
development, and no regulation of cell cycle was observed. Thus in
FSHD cells miRNA dysregulation affects two important aspects of
differentiation leading to a defect in myogenesis. These data are in
agreement with previously reported studies [9,10,20].
By the NGS approach we derived that FSHD myogenesis is
characterized by a profound dysregulation of miRNA expression
showing the involvement of at least 38 known miRNAs, including
the myomiRs and possibly three novel miRNAs, but excluding
small RNAs previously reported to derive from the D4Z4 array
[14]. This and previous works have clearly demonstrated that
FSHD cells are characterized by a global dysregulation of mRNA,
miRNA and protein expression essentially affecting the myogenic
process [9,10,11,21,24,44].
The up-regulation of the last DUX4 gene in individual showing
a reduced numbers (#8) of D4Z4 repeats at 4q35 combined with a
specific molecular signature (4A(159/161/168) DUX4 polyade-
nylation signal (PA) haplotype) is supposed to underlie FSHD
pathophysiology [6]. However, it has been recently reported that
1.3% of healthy individuals carry the same molecular signature
and 19% of subjects affected by FSHD do not carry alleles with
eight or fewer D4Z4 repeats [8]. Furthermore, a dysregulation of
genes involved in myogenesis has been recently observed in FSHD
fetuses; importantly, the DUX4-fl pathogenic transcript was
detected in both FSHD and control samples [45], as well as in
unaffected individuals, but not in all FSHD cases [8]. These data
suggest that the molecular basis of FSHD might not be simply
based on the overexpression of the single DUX4 gene, but rather
from a cascade of dysregulation mediated by the D4Z4 array
contraction. This structural alteration, as previously shown, might
induce conformational changes in the 4q35 region itself, and
perhaps elsewhere in the human genome [46,47]. Furthermore, in
the dysregulation cascade could also play a role lncRNAs, such as
DBE-T [7].
Conclusions
By using the NGS approach, we derived the complete pattern of
miRNAs regulating in vitro control and FSHD myogenesis. In
addition to confirming previously reported FSHD-related miR-
NAs, we identified additional known and novel miRNAs that are
differentially expressed between FSHD and control myogenesis
and thus potentially contributing to the FSHD pathogenic
mechanism. In general, the comparison of control and FSHD
myogenesis reveals that the dystrophy is characterized by a
complex alteration of miRNA expression, which also includes the
significant down-regulation of myomiRs at late stages of differen-
tiation, thus essentially affecting muscle differentiation and
development.
Thus, the full range of molecular alteration(s) at the basis of
FSHD is not yet fully deciphered and the miRNA profiling we
derive could represent a novel molecular signature for FSHD that
includes diagnostic biomarkers and possibly therapeutic targets.
Materials and Methods
Cell lines
Primary FSHD and control cell lines were obtained from
Myobank-AFM (Institut de Myologie-Groupe Hospitalier Pitie´-
Salpetrie`re, Paris) and Boston Biomedical Research Institute
(BBRI, Senator Paul D. Wellstone Muscular Dystrophy Cooper-
ative, Research Center for FSHD). Six cell lines derived from
biopsies of different healthy and FSHD muscles including vastus,
tensor fascia lata, quadriceps femoris (controls) and ilio-psoas and
rhomboid (FSHD) (Table S1) were used for deep small RNA
sequencing. In addition, to these cell lines, five control and four
FSHD cell lines from deltoid and biceps [48] (Table S1) were used
to validate deep sequencing data by qRT-PCR. FSHD primary
cell lines were derived from biopsies of mild or not affected
muscles and showed a D4Z4 array contraction ranging from 5.9 to
28 kb as determined by Southern Blot after EcoRI/BnlI digestion.
The results reported below were derived by the analysis of all the
cell lines listed in Table S1, comprising nine controls and seven
FSHD and thus including also the cells used for NGS. Control and
FSHD myoblasts were at low population doubling (from 2 to 7)
and highly comparable for the expression of the muscular marker
Desmin (96–97%) and the proliferation marker Ki67 (62–65%), as
determined by immunofluorescence (Fig. S1). Furthermore,
control and FSHD cell lines showed a comparable extent of
differentiation as demonstrated by the down-regulation of the
proliferation marker Ki67 (by immunofluorescence) and of MYF5
(by qRT-PCR), and by the up-regulation of MYOG (by qRT-
PCR), MYOD (by Western blot) and MHC (by qRT-PCR and
Western blot), as well as a comparable extent of fusion index (40–
45%) (Fig. S1). In addition, FSHD and control myoblasts and
myotubes appeared similar when analyzed by immunofluores-
cence. The cell lines used for NGS originated results in the average
comparable to those shown in Fig. S1. Cells were cultured as
described in guidelines of BBRI and Cheli et al [9].
Immunofluorescence, image acquisition and analysis
Cell immunofluorescence was performed as described [49], with
antibodies specific for Desmin (rAb, Sigma Aldrich), ki67 (rAb,
Vector) and sarcomeric myosin MHC (MF20, from Developmen-
tal Studies Hybridoma Bank). Appropriate secondary antibodies
conjugated with Alexa 488 (green, Cell Signalling) or Alexa 568
(red; Cell Signalling) were used for fluorescence detection, Nuclei
were stained with Hoechst Stain Solution (H6024, SIGMA).
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Fluorescent images were taken on confocal laser scanning
microscope (Zeiss Lsm 01, Biorad mrc 600, Biorad 1024) using
126magnification. Images showing double or triple fluorescence
were separately acquired using appropriate filters, and the
different layers were merged with ImageJ software.
For all control and FSHD cell lines used in this study, the
quantification of Desmin and ki67 positive cells has been
performed on myoblasts and myotubes. Furthermore, for all
control and FSHD cell lines, the absolute fusion index has been
calculated as the percentage of MHC-positive nuclei over total
number of nuclei after 7 days in differentiation medium.
An average value was determined by counting cells (200–300
cells/field) in at least 5 microscopic fields per sample at 126
magnification.
RNA isolation and deep sequencing
Total RNA was isolated with the mirVana miRNA isolation kit
(cat.# AM1560, Life Technologies) from myoblast cell lines
derived from 3 FSHD patients and 3 control subjects, before and
after in vitro differentiation. RNA was quantified by Nanodrop
spectrophotometer (Thermo Scientific) and its integrity was
evaluated on an Experion automated electrophoresis system
(Bio-Rad); all samples had a RNA Quality Indicator (RQI) value
$9.
20 micrograms of total RNA were used for PAGE purification
of small RNA molecules shorter than 35 nucleotides, adaptor
ligation, and small RNA library preparation. The obtained
libraries were sequenced on a HiSeq 2000 platform (Illumina) at
BGI, Hong Kong, giving approximately 12 million high quality
reads per sample (submitted to SRA database under acc. number
SRP034654).
Sequencing data analysis
MicroRNA differential expression analysis was performed using
R/Bioconductor, by following the workflow implemented in the
oneChannelGUI interface [50,51]. Briefly, adaptor sequences
were trimmed from fastq files using a specific perl script, and then
sequences were aligned to the reference human miRBase v.20
precursor dataset (www.mirbase.org) using bowtie 1.0.0. Data
were filtered for count threshold (.8 reads in 50% of samples
analyzed) and pairwise comparisons of differential miRNA
expression were performed using DEseq (log2FC§2; p-value,
0.05). Hierarchical clustering of differentially expressed miRNA
was performed with dChip (version 2010.01; https://sites.google.
com/site/dchipsoft/).
Identification of novel miRNAs
After excluding all reads that matched known small RNA classes
annotated in miRBase v.20 (known miRNAs) and Rfam (e.g.
tRNA, snRNA, snoRNA), putative novel miRNAs were predicted
using mireap (http://sourceforge.net/projects/mireap/). The
program predicts novel miRNAs from deep sequenced small
RNA libraries by taking into consideration miRNA biogenesis,
sequencing depth, and structural features (hairpin structure and
stability) to improve the sensitivity and specificity of miRNA
identification. Among predicted novel miRNAs, we considered as
plausible candidates those matching the following criteria: 1) the
detection in several samples (at least 2 out of 3 samples of one or
more experimental groups); 2) the mature miRNA had sufficient
sequence support (at least a mean of 10 reads for each
experimental group); 3) the sequence did not match to known
miRNAs in miRBase v.20.
Quantitative Real-time PCR
Quantitative RT-PCR (qRT-PCR) analysis was performed on
7900 HT Fast Real-Time PCR System (Applied Biosystems) by
TaqMan small RNA Assays to validate the miRNA sequencing
data. The miRNA specific probes were from Applied Biosystems.
150 ng RNA was reverse transcribed by TaqMan MicroRNA
Reverse Transcription Kit (cat.# 4366596; Applied Biosystems) at
16uC for 30 min, 42uC for 30 min and 85uC for 5 min. Each
amplicon was analyzed in duplicate in 96-well plates. TaqMan
small RNA Assays reactions were performed following manufac-
turer’s protocol (cat.# 4440048; Applied Biosystems). RNU48 was
used for normalization. Thermal cycling conditions for real time
PCR were 2 min at 95uC, followed by 40 cycles at 95uC for 10 s
and 60uC for 30 s. Results were analyzed using the comparative
22DDCt method. qRT-PCR experiments for MYF5, MYOG,
MHC and GAPDH gene expression analysis were performed as
described [9]. The statistical analysis was performed using a two-
tail unpaired t-test and the error bars on the graphs are referred to
standard deviation. qRT-PCR probes and primers are listed in
Table S2.
Derivation of target genes
The putative miRNAs target genes were predicted by
TargetScan Human (http://www.targetscan.org/) [52]. The
prediction tool is based on different parameters such as
complementarity to the seed region, 39 complementarity, local
AU content, position contribution and conservation in different
species [22]. Predicted target genes were then filtered on the basis
of their inverse correlation with the expression of mRNAs of two
different chip analysis on Affymetrix human exon 1.0 ST array
[9,10], using a FC$1.5 and a p-value,0.05.
Pathway and functional annotation analysis
The derived predicted target genes, inversely correlated to the
miRNAs expression, were subjected to the analysis of Gene
Ontology terms (biological processes) by DAVID (Database for
Annotation, Visualization and Integrated Discovery, v6.7) [53,54].
The target genes were mapped to the GO annotation dataset, and
the enriched biological processes were extracted using the EASE
score, a modified Fisher exact p-value.
Protein extracts and Immunoblot analysis
Cells were collected in RIPA Buffer (50 mM TrisHCl pH=7,4,
150 mM NaCl, 0,1% SDS, 0,5% Deoxycholate Sodium, 1% NP-
40 and protease inhibitor cocktail 1X-cat.# P2714-1BTL, Sigma
MO, USA), and centrifuged 15 minutes at 13000 rpm at 4uC to
discard cellular debris. Sample preparation and Western blot
analyses were performed as described in Pisconti et al [55]. After
electrophoresis, polypeptides were electrophoretically transferred
to nitrocellulose filters (Thermo Scientific) and antigens revealed
by the respective primary Abs and the appropriate secondary Abs,
through autoradiography using enhanced chemiluminescence
(LiteAblot Plus, cat.# EMP011005, Euroclone). In Western blot
analyses, primary antibodies against MHC (MF20, from Devel-
opmental Studies Hybridoma Bank), MYOD (cat.# sc-31942,
Santa Cruz) and housekeeping gene GAPDH (cat.# G8795;
Sigma) were used.
Supporting Information
Figure S1 Characterization of control and FSHD myoblasts cell
lines. A) Example of immunostaining experiment on proliferating
and differentiated primary myoblasts (control: MX01010MBS;
FSHD: MX04309MBS). Images have been taken at confocal laser
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scanning microscope at 126 magnification. Nuclei were stained
with Hoescht (blue). Panels I–IV show localization of Desmin and
Ki67 in proliferating myoblasts; panels I–II show immunostaining
experiment using the polyclonal anti-Desmin (red); panels II–IV
show immunostaining experiment using the polyclonal anti-Ki67
(red). Panels V–VIII show co-localization of Desmin or Ki67 and
MHC on differentiated primary myoblasts: panels V–VI show
immunostaining with polyclonal anti-Desmin and monoclonal
anti-MHC (Ab-Desmin-red and Ab-MHC-green); panels VII–
VIII show immunostaining with polyclonal anti-Ki67 and
monoclonal anti-MHC (Ab-Ki67-red and Ab-MHC-green). Scale
bar = 100 mm. B) Percentage of Desmin and Ki67 positive cells in
myoblasts and myotubes after 7 days of differentiation derived
from immunostaining with appropriate antibodies (Ab-Desmin
and Ab-Ki67). Results are expressed as mean6SD of independent
experiments performed on all cell lines described in Table S1. C)
Absolute fusion index was determined at day 7 of differentiation
(D7), counting the percentage of MHC- positive nuclei over the
total number of nuclei. An average value was determined by
counting cells in at least 5 microscopic fields (200–300 cells/field).
Results are expressed as mean6SD of independent experiments
performed on all cell lines (see Table S1). *p,0.05. D) Myogenic
differentiation was evaluated by qRT-PCR analysis for MYF5,
MYOG, MHC expression. All data points were calculated in
triplicate as gene expression relative to endogenous GAPDH
expression. Data are represented as the mean6SD of independent
experiments performed on all cell lines described in Table S1.
GM: growth medium; 7D: seven days of differentiation. *p,0.05,
**p,0.01. E) Example of Western blot analysis with specific
antibodies against MYOD and MHC in control and FSHD
myoblasts at different time points during myogenic differentiation
(GM: growth medium; 3D: three days of differentiation; 7D: seven
days of differentiation). GAPDH protein level was used as an
internal loading control. Graphs show mean values 6SD obtained
from the ratio of densitometric values of protein/GAPDH bands.
Data are representative of independent experiments performed on
all cell lines described in Table S1. The Western blot in E shows a
representative experiment (control: MX01010MBS; FSHD:
MX04309MBS). *p,0.05, **p,0.01.
(TIF)
Figure S2 Scatter plots of the reads of miRNAs modulated in
control and FSHD myogenesis. C1: MX01010MBS; C2:
MX03609MBS; C3: MX01110MBS, Control cell lines;
F1:MX00409MBS; F2: MX03010MBS; F3:MX04309MBS,
FSHD cell lines (see Table S1).
(PDF)
Figure S3 Authentication of NGS data by qRT-PCR. qRT-
PCR analysis of myomiRs (miR-1, miR-133a and miR-206)
during control and FSHD myogenesis at 0 and 7 days of
differentiation on the three control and three FSHD cell lines used
in the NGS experiment (MX01010MBS; MX03609MBS;
MX01110MBS, MX00409MBS; MX03010MBS;
MX04309MBS). GM: growth medium; 7D: seven days of
differentiation. *p,0.05; **p,0.01.
(TIF)
Table S1 Primary myoblasts cell lines used in this study. Cell
lines have been obtained from Myobank-AFM Istitut de Myologie
(Paris)*and Boston Biomedical Research Institute (BBRI, Boston).
(XLSX)
Table S2 Taqman probes and primers used in qRT-PCR
experiments.
(XLSX)
Table S3 List of microRNAs modulated in control myogenesis
resulting by DEseq analysis.
(XLSX)
Table S4 List of microRNAs modulated in FSHD myogenesis
resulting by DEseq analysis.
(XLSX)
Table S5 List of microRNAs modulated in FSHD vs control
myotubes resulting by DEseq analysis.
(XLSX)
Table S6 Potentially ‘‘validated’’ targets. List of predicted target
genes of miRNAs modulated in control myogenesis, filtered on
GSE26061 [9] and GSE26145 [10].
(XLSX)
Table S7 Potentially ‘‘validated’’ targets. List of predicted target
genes of miRNAs modulated in FSHD myogenesis, filtered on
GSE26061 [9] and GSE26145 [10].
(XLSX)
Table S8 Novel miRNAs predicted by mireap.
(XLSX)
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